Melatonin and its relation to the immune system and inflammation.
Level 5 - mechanism / opinion, no new human data
Narrative review describing mechanistic biological pathways without empirical clinical trial data.
PubMed 11268363 · doi:10.1111/j.1749-6632.2000.tb05402.x
What was done
This narrative review summarizes literature regarding the presence of melatonin in extrapineal tissues (including the retina, bone marrow cells, and bile) and outlines its biological mechanisms in modulating inflammation and immune responses.
What was found
The abstract reports purely qualitative mechanistic pathways and provides no quantitative data. Melatonin directly scavenges free radicals and reactive oxygen and nitrogen species, including hydroxyl radicals (.OH), peroxynitrite (ONOO-), and hypochlorous acid (HOCl). It inhibits nuclear factor-kappa B (NF-κB) nuclear translocation and DNA binding, reducing downstream expression of proinflammatory cytokines (including interleukins and tumor necrosis factor-alpha). Additionally, indirect evidence indicates it inhibits adhesion molecule expression, decreasing leukocyte sticking, transendothelial migration, and tissue edema.
Why it matters
It maps key molecular mechanisms—spanning direct antioxidant actions to transcriptional regulation—through which melatonin may mitigate tissue destruction during inflammatory processes.
Limits
The abstract contains no quantitative metrics, specific study designs, or patient sample sizes. Findings are mechanistic and preclinical, offering no direct evidence regarding clinical efficacy, optimal dosing, or safety outcomes in human inflammatory disorders.
Cited by
- supports Melatonin can inhibit the translocation of nuclear factor kappa B (NF-κB) to the nucleus, thereby blunting the production of pro-inflammatory cytokines.